Share Price and Basic Stock Data
Last Updated: January 8, 2026, 7:48 am
| PEG Ratio | 4.91 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Pfizer Ltd, a prominent player in the Indian pharmaceuticals industry, reported a share price of ₹4,928 and a market capitalization of ₹22,539 Cr. for the period ending September 2023. The company has demonstrated fluctuating revenue trends, with total sales reaching ₹2,425 Cr. in March 2023, a decline from ₹2,611 Cr. in March 2022. The quarterly sales figures illustrate this volatility: ₹637 Cr. in September 2022 dropped to ₹531 Cr. by June 2023, before recovering slightly to ₹575 Cr. in September 2023. The trailing twelve months (TTM) revenue stood at ₹2,375 Cr., indicating a modest recovery trajectory. Sales have been pressured by various market dynamics, reflecting the competitive landscape of the pharmaceutical sector. Despite these challenges, the company continues to maintain a solid operational framework, supported by a robust portfolio of products.
Profitability and Efficiency Metrics
In terms of profitability, Pfizer Ltd’s operating profit margin (OPM) reported at 36% indicates a strong operational efficiency relative to industry averages. The net profit for the fiscal year ending March 2025 was ₹768 Cr., with an impressive net profit margin of 33.64%, which is higher than typical sector benchmarks. The company recorded a return on equity (ROE) of 16.4% and a return on capital employed (ROCE) of 21.6%, showcasing effective utilization of equity and capital. However, the cash conversion cycle (CCC) stood at 177 days, reflecting potential inefficiencies in managing working capital. The interest coverage ratio (ICR) was notably high at 108.50x, highlighting the company’s strong ability to service its debt, which remained low at ₹43 Cr. This combination of strong profitability metrics and efficient capital management underscores Pfizer’s operational strength in a competitive environment.
Balance Sheet Strength and Financial Ratios
Pfizer Ltd’s balance sheet reveals a robust financial structure, characterized by total reserves amounting to ₹3,803 Cr. and minimal borrowings of ₹43 Cr. This low leverage indicates a conservative approach to financing, providing a cushion against market volatility. The company’s book value per share increased to ₹921.84 in March 2025, up from ₹701.05 in March 2023, indicating growth in shareholder equity. The current ratio stood at a healthy 6.17, suggesting a strong liquidity position, while the quick ratio was recorded at 5.33, further affirming the company’s short-term financial health. Additionally, the price-to-book value (P/BV) ratio of 4.34x reflects investor confidence in the company’s growth prospects. Overall, Pfizer’s balance sheet strength positions it favorably compared to industry peers, enabling it to navigate challenges effectively.
Shareholding Pattern and Investor Confidence
The shareholding structure of Pfizer Ltd indicates a stable promoter holding of 63.92%, reflecting strong internal confidence in the company’s future. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), held 2.60% and 17.11% respectively, indicating a moderate interest from institutional players. The number of shareholders stood at 1,03,480, suggesting a broad base of retail participation. Notably, the public shareholding has gradually decreased from 18.39% in December 2022 to 16.37% by September 2025, which may raise concerns regarding retail investor confidence. The dividend payout ratio for March 2025 was reported at 20.86%, which, while conservative, reflects a commitment to returning value to shareholders. This mix of stable promoter ownership and cautious dividend policies may influence investor perceptions positively.
Outlook, Risks, and Final Insight
Looking forward, Pfizer Ltd faces a blend of opportunities and challenges. The company’s strong financial metrics, including a high interest coverage ratio and solid profitability margins, position it well for future growth. However, risks such as fluctuating sales trends and a lengthy cash conversion cycle could impact operational efficiency. Furthermore, the pharmaceutical sector’s competitive nature may pressure profit margins. If Pfizer can enhance its working capital management and adapt to market demands, it could sustain its growth trajectory. Conversely, failure to address these operational inefficiencies might hinder performance. Overall, while the company is well-equipped to handle current challenges, strategic focus on efficiency and market responsiveness will be crucial for maintaining investor confidence and achieving long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 210/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,543 Cr. | 417 | 479/192 | 94.1 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.2 Cr. | 47.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 57.1 Cr. | 39.0 | 40.0/17.0 | 136 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,848.86 Cr | 1,158.96 | 53.61 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 637 | 622 | 573 | 531 | 575 | 540 | 547 | 563 | 589 | 538 | 592 | 603 | 642 |
| Expenses | 406 | 418 | 391 | 421 | 393 | 387 | 357 | 385 | 399 | 392 | 364 | 393 | 412 |
| Operating Profit | 232 | 203 | 182 | 111 | 183 | 153 | 189 | 177 | 189 | 146 | 228 | 210 | 230 |
| OPM % | 36% | 33% | 32% | 21% | 32% | 28% | 35% | 32% | 32% | 27% | 38% | 35% | 36% |
| Other Income | 213 | 27 | 12 | 33 | 36 | 44 | 75 | 42 | 43 | 43 | 217 | 67 | 42 |
| Interest | 3 | 4 | 3 | 3 | 3 | 3 | 7 | 2 | 2 | 2 | 3 | 3 | 2 |
| Depreciation | 26 | 26 | 26 | 16 | 15 | 18 | 14 | 15 | 15 | 15 | 16 | 14 | 14 |
| Profit before tax | 415 | 201 | 165 | 126 | 201 | 176 | 244 | 203 | 215 | 172 | 426 | 260 | 255 |
| Tax % | 25% | 25% | 21% | 26% | 26% | 26% | 27% | 26% | 26% | 26% | 22% | 26% | 26% |
| Net Profit | 311 | 151 | 130 | 94 | 149 | 130 | 179 | 151 | 158 | 128 | 331 | 192 | 189 |
| EPS in Rs | 68.00 | 32.93 | 28.34 | 20.44 | 32.56 | 28.41 | 39.10 | 32.94 | 34.61 | 27.89 | 72.34 | 41.91 | 41.32 |
Last Updated: December 29, 2025, 3:33 pm
Below is a detailed analysis of the quarterly data for Pfizer Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 642.00 Cr.. The value appears strong and on an upward trend. It has increased from 603.00 Cr. (Jun 2025) to 642.00 Cr., marking an increase of 39.00 Cr..
- For Expenses, as of Sep 2025, the value is 412.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 393.00 Cr. (Jun 2025) to 412.00 Cr., marking an increase of 19.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 230.00 Cr.. The value appears strong and on an upward trend. It has increased from 210.00 Cr. (Jun 2025) to 230.00 Cr., marking an increase of 20.00 Cr..
- For OPM %, as of Sep 2025, the value is 36.00%. The value appears strong and on an upward trend. It has increased from 35.00% (Jun 2025) to 36.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 42.00 Cr.. The value appears to be declining and may need further review. It has decreased from 67.00 Cr. (Jun 2025) to 42.00 Cr., marking a decrease of 25.00 Cr..
- For Interest, as of Sep 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3.00 Cr. (Jun 2025) to 2.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 14.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 255.00 Cr.. The value appears to be declining and may need further review. It has decreased from 260.00 Cr. (Jun 2025) to 255.00 Cr., marking a decrease of 5.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 26.00%.
- For Net Profit, as of Sep 2025, the value is 189.00 Cr.. The value appears to be declining and may need further review. It has decreased from 192.00 Cr. (Jun 2025) to 189.00 Cr., marking a decrease of 3.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 41.32. The value appears to be declining and may need further review. It has decreased from 41.91 (Jun 2025) to 41.32, marking a decrease of 0.59.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:50 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,112 | 1,853 | 2,012 | 1,966 | 1,969 | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | 2,193 | 2,281 | 2,375 |
| Expenses | 872 | 1,438 | 1,579 | 1,616 | 1,468 | 1,516 | 1,578 | 1,526 | 1,775 | 1,616 | 1,555 | 1,540 | 1,562 |
| Operating Profit | 239 | 414 | 433 | 350 | 501 | 566 | 574 | 712 | 836 | 809 | 638 | 742 | 813 |
| OPM % | 22% | 22% | 22% | 18% | 25% | 27% | 27% | 32% | 32% | 33% | 29% | 33% | 34% |
| Other Income | 109 | 44 | 97 | 232 | 114 | 167 | 183 | 81 | 63 | 134 | 185 | 344 | 369 |
| Interest | 1 | 2 | 1 | 2 | 1 | 2 | 11 | 15 | 11 | 13 | 15 | 8 | 10 |
| Depreciation | 8 | 250 | 58 | 63 | 66 | 71 | 103 | 109 | 115 | 106 | 62 | 61 | 60 |
| Profit before tax | 340 | 207 | 470 | 517 | 548 | 660 | 642 | 669 | 773 | 824 | 746 | 1,016 | 1,113 |
| Tax % | 35% | 66% | 35% | 35% | 34% | 35% | 21% | 26% | 21% | 24% | 26% | 24% | |
| Net Profit | 221 | 70 | 305 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 768 | 839 |
| EPS in Rs | 74.01 | 15.26 | 66.67 | 73.62 | 78.71 | 93.79 | 111.29 | 108.77 | 133.90 | 136.38 | 120.52 | 167.79 | 183.46 |
| Dividend Payout % | 486% | 82% | 22% | 27% | 25% | 24% | 297% | 32% | 26% | 51% | 29% | 98% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -68.33% | 335.71% | 10.49% | 6.82% | 19.17% | 18.65% | -2.16% | 23.09% | 1.79% | -11.70% | 39.38% |
| Change in YoY Net Profit Growth (%) | 0.00% | 404.04% | -325.22% | -3.67% | 12.34% | -0.52% | -20.81% | 25.25% | -21.30% | -13.49% | 51.08% |
Pfizer Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 1% |
| 3 Years: | -4% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 5% |
| 3 Years: | 2% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 2% |
| 3 Years: | 6% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 18% |
| 3 Years: | 17% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 12:15 pm
Balance Sheet
Last Updated: January 7, 2026, 4:12 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 30 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
| Reserves | 629 | 1,927 | 2,118 | 2,373 | 2,637 | 2,966 | 3,350 | 2,347 | 2,819 | 3,162 | 3,550 | 4,172 | 3,803 |
| Borrowings | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 63 | 39 | 41 | 40 | 41 | 43 |
| Other Liabilities | 318 | 638 | 722 | 840 | 1,004 | 926 | 1,007 | 810 | 997 | 752 | 593 | 653 | 714 |
| Total Liabilities | 977 | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,606 |
| Fixed Assets | 20 | 944 | 925 | 902 | 950 | 886 | 973 | 894 | 869 | 749 | 713 | 724 | 701 |
| CWIP | 3 | 13 | 3 | 15 | 1 | 0 | 1 | 3 | 1 | 8 | 0 | 8 | 8 |
| Investments | 44 | 43 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 909 | 1,614 | 1,923 | 2,343 | 2,739 | 3,054 | 3,432 | 2,369 | 3,030 | 3,244 | 3,516 | 4,180 | 3,897 |
| Total Assets | 977 | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,606 |
Below is a detailed analysis of the balance sheet data for Pfizer Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 46.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 46.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,803.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,172.00 Cr. (Mar 2025) to 3,803.00 Cr., marking a decrease of 369.00 Cr..
- For Borrowings, as of Sep 2025, the value is 43.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 41.00 Cr. (Mar 2025) to 43.00 Cr., marking an increase of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 714.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 653.00 Cr. (Mar 2025) to 714.00 Cr., marking an increase of 61.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 4,606.00 Cr.. The value appears to be improving (decreasing). It has decreased from 4,911.00 Cr. (Mar 2025) to 4,606.00 Cr., marking a decrease of 305.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 701.00 Cr.. The value appears to be declining and may need further review. It has decreased from 724.00 Cr. (Mar 2025) to 701.00 Cr., marking a decrease of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,897.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,180.00 Cr. (Mar 2025) to 3,897.00 Cr., marking a decrease of 283.00 Cr..
- For Total Assets, as of Sep 2025, the value is 4,606.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,911.00 Cr. (Mar 2025) to 4,606.00 Cr., marking a decrease of 305.00 Cr..
Notably, the Reserves (3,803.00 Cr.) exceed the Borrowings (43.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 239.00 | 412.00 | 431.00 | 348.00 | 499.00 | 564.00 | 572.00 | 649.00 | 797.00 | 768.00 | 598.00 | 701.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 57 | 32 | 26 | 20 | 29 | 30 | 29 | 18 | 20 | 23 | 31 | 31 |
| Inventory Days | 148 | 191 | 167 | 148 | 147 | 189 | 198 | 199 | 173 | 175 | 200 | 214 |
| Days Payable | 156 | 165 | 157 | 178 | 245 | 213 | 197 | 130 | 102 | 91 | 77 | 68 |
| Cash Conversion Cycle | 49 | 58 | 36 | -10 | -69 | 6 | 31 | 87 | 91 | 107 | 154 | 177 |
| Working Capital Days | 25 | 7 | -9 | -47 | -57 | -16 | -8 | 3 | -14 | -4 | 24 | 23 |
| ROCE % | 29% | 24% | 22% | 17% | 21% | 23% | 20% | 23% | 29% | 26% | 22% | 22% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 1,206,103 | 0.88 | 600.04 | 947,910 | 2025-12-08 07:42:13 | 27.24% |
| Quant Small Cap Fund | 914,527 | 1.51 | 454.98 | 875,027 | 2025-12-15 09:05:47 | 4.51% |
| Nippon India Multi Cap Fund | 362,848 | 0.36 | 180.52 | 362,848 | 2025-04-22 15:56:54 | 0% |
| ICICI Prudential Value Fund | 328,943 | 0.27 | 163.65 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 318,249 | 1.87 | 158.33 | 293,249 | 2025-12-08 04:19:42 | 8.53% |
| ICICI Prudential Smallcap Fund | 288,602 | 1.7 | 143.58 | 230,129 | 2025-12-14 01:36:52 | 25.41% |
| UTI Mid Cap Fund | 246,276 | 1.02 | 122.52 | N/A | N/A | N/A |
| DSP Healthcare Fund | 200,644 | 3.14 | 99.82 | N/A | N/A | N/A |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 180,970 | 1.39 | 90.03 | N/A | N/A | N/A |
| DSP Large & Mid Cap Fund | 178,101 | 0.51 | 88.61 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 136.46 | 120.51 | 128.50 | 133.89 | 108.77 |
| Diluted EPS (Rs.) | 167.79 | 120.51 | 136.38 | 133.89 | 108.77 |
| Cash EPS (Rs.) | 181.07 | 134.12 | 159.44 | 159.03 | 132.68 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 921.84 | 785.91 | 701.05 | 626.10 | 523.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 921.84 | 785.91 | 701.05 | 626.10 | 523.07 |
| Dividend / Share (Rs.) | 165.00 | 35.00 | 70.00 | 35.00 | 35.00 |
| Revenue From Operations / Share (Rs.) | 498.65 | 479.38 | 530.00 | 570.71 | 489.30 |
| PBDIT / Share (Rs.) | 199.45 | 178.32 | 198.89 | 196.37 | 173.38 |
| PBIT / Share (Rs.) | 186.16 | 164.71 | 175.82 | 171.23 | 149.47 |
| PBT / Share (Rs.) | 222.10 | 163.07 | 180.11 | 168.94 | 146.17 |
| Net Profit / Share (Rs.) | 167.78 | 120.51 | 136.38 | 133.89 | 108.77 |
| PBDIT Margin (%) | 39.99 | 37.19 | 37.52 | 34.40 | 35.43 |
| PBIT Margin (%) | 37.33 | 34.35 | 33.17 | 30.00 | 30.54 |
| PBT Margin (%) | 44.53 | 34.01 | 33.98 | 29.60 | 29.87 |
| Net Profit Margin (%) | 33.64 | 25.13 | 25.73 | 23.46 | 22.22 |
| Return on Networth / Equity (%) | 18.20 | 15.33 | 19.45 | 21.38 | 20.79 |
| Return on Capital Employeed (%) | 19.61 | 20.46 | 24.05 | 25.70 | 27.44 |
| Return On Assets (%) | 15.62 | 13.03 | 15.59 | 15.70 | 15.23 |
| Asset Turnover Ratio (%) | 0.49 | 0.53 | 0.61 | 0.72 | 0.58 |
| Current Ratio (X) | 6.17 | 5.07 | 3.84 | 2.81 | 2.49 |
| Quick Ratio (X) | 5.33 | 4.27 | 3.21 | 2.28 | 1.92 |
| Inventory Turnover Ratio (X) | 5.02 | 0.78 | 0.79 | 0.80 | 0.77 |
| Dividend Payout Ratio (NP) (%) | 20.86 | 33.19 | 47.65 | 26.13 | 303.38 |
| Dividend Payout Ratio (CP) (%) | 19.33 | 29.82 | 40.76 | 22.00 | 248.70 |
| Earning Retention Ratio (%) | 79.14 | 66.81 | 52.35 | 73.87 | -203.38 |
| Cash Earning Retention Ratio (%) | 80.67 | 70.18 | 59.24 | 78.00 | -148.70 |
| Interest Coverage Ratio (X) | 108.50 | 52.94 | 67.95 | 85.64 | 52.50 |
| Interest Coverage Ratio (Post Tax) (X) | 71.72 | 36.26 | 45.13 | 59.39 | 33.93 |
| Enterprise Value (Cr.) | 15519.59 | 17140.82 | 13990.32 | 18276.37 | 19572.81 |
| EV / Net Operating Revenue (X) | 6.80 | 7.82 | 5.77 | 7.00 | 8.74 |
| EV / EBITDA (X) | 17.01 | 21.01 | 15.38 | 20.34 | 24.67 |
| MarketCap / Net Operating Revenue (X) | 8.03 | 8.75 | 6.54 | 7.62 | 9.24 |
| Retention Ratios (%) | 79.13 | 66.80 | 52.34 | 73.86 | -203.38 |
| Price / BV (X) | 4.34 | 5.34 | 4.94 | 6.95 | 8.64 |
| Price / Net Operating Revenue (X) | 8.03 | 8.75 | 6.54 | 7.62 | 9.24 |
| EarningsYield | 0.04 | 0.02 | 0.03 | 0.03 | 0.02 |
After reviewing the key financial ratios for Pfizer Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 136.46. This value is within the healthy range. It has increased from 120.51 (Mar 24) to 136.46, marking an increase of 15.95.
- For Diluted EPS (Rs.), as of Mar 25, the value is 167.79. This value is within the healthy range. It has increased from 120.51 (Mar 24) to 167.79, marking an increase of 47.28.
- For Cash EPS (Rs.), as of Mar 25, the value is 181.07. This value is within the healthy range. It has increased from 134.12 (Mar 24) to 181.07, marking an increase of 46.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 921.84. It has increased from 785.91 (Mar 24) to 921.84, marking an increase of 135.93.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 921.84. It has increased from 785.91 (Mar 24) to 921.84, marking an increase of 135.93.
- For Dividend / Share (Rs.), as of Mar 25, the value is 165.00. This value exceeds the healthy maximum of 3. It has increased from 35.00 (Mar 24) to 165.00, marking an increase of 130.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 498.65. It has increased from 479.38 (Mar 24) to 498.65, marking an increase of 19.27.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 199.45. This value is within the healthy range. It has increased from 178.32 (Mar 24) to 199.45, marking an increase of 21.13.
- For PBIT / Share (Rs.), as of Mar 25, the value is 186.16. This value is within the healthy range. It has increased from 164.71 (Mar 24) to 186.16, marking an increase of 21.45.
- For PBT / Share (Rs.), as of Mar 25, the value is 222.10. This value is within the healthy range. It has increased from 163.07 (Mar 24) to 222.10, marking an increase of 59.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 167.78. This value is within the healthy range. It has increased from 120.51 (Mar 24) to 167.78, marking an increase of 47.27.
- For PBDIT Margin (%), as of Mar 25, the value is 39.99. This value is within the healthy range. It has increased from 37.19 (Mar 24) to 39.99, marking an increase of 2.80.
- For PBIT Margin (%), as of Mar 25, the value is 37.33. This value exceeds the healthy maximum of 20. It has increased from 34.35 (Mar 24) to 37.33, marking an increase of 2.98.
- For PBT Margin (%), as of Mar 25, the value is 44.53. This value is within the healthy range. It has increased from 34.01 (Mar 24) to 44.53, marking an increase of 10.52.
- For Net Profit Margin (%), as of Mar 25, the value is 33.64. This value exceeds the healthy maximum of 10. It has increased from 25.13 (Mar 24) to 33.64, marking an increase of 8.51.
- For Return on Networth / Equity (%), as of Mar 25, the value is 18.20. This value is within the healthy range. It has increased from 15.33 (Mar 24) to 18.20, marking an increase of 2.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is 19.61. This value is within the healthy range. It has decreased from 20.46 (Mar 24) to 19.61, marking a decrease of 0.85.
- For Return On Assets (%), as of Mar 25, the value is 15.62. This value is within the healthy range. It has increased from 13.03 (Mar 24) to 15.62, marking an increase of 2.59.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.49. It has decreased from 0.53 (Mar 24) to 0.49, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 6.17. This value exceeds the healthy maximum of 3. It has increased from 5.07 (Mar 24) to 6.17, marking an increase of 1.10.
- For Quick Ratio (X), as of Mar 25, the value is 5.33. This value exceeds the healthy maximum of 2. It has increased from 4.27 (Mar 24) to 5.33, marking an increase of 1.06.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.02. This value is within the healthy range. It has increased from 0.78 (Mar 24) to 5.02, marking an increase of 4.24.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 20.86. This value is within the healthy range. It has decreased from 33.19 (Mar 24) to 20.86, marking a decrease of 12.33.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 19.33. This value is below the healthy minimum of 20. It has decreased from 29.82 (Mar 24) to 19.33, marking a decrease of 10.49.
- For Earning Retention Ratio (%), as of Mar 25, the value is 79.14. This value exceeds the healthy maximum of 70. It has increased from 66.81 (Mar 24) to 79.14, marking an increase of 12.33.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 80.67. This value exceeds the healthy maximum of 70. It has increased from 70.18 (Mar 24) to 80.67, marking an increase of 10.49.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 108.50. This value is within the healthy range. It has increased from 52.94 (Mar 24) to 108.50, marking an increase of 55.56.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 71.72. This value is within the healthy range. It has increased from 36.26 (Mar 24) to 71.72, marking an increase of 35.46.
- For Enterprise Value (Cr.), as of Mar 25, the value is 15,519.59. It has decreased from 17,140.82 (Mar 24) to 15,519.59, marking a decrease of 1,621.23.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.80. This value exceeds the healthy maximum of 3. It has decreased from 7.82 (Mar 24) to 6.80, marking a decrease of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 17.01. This value exceeds the healthy maximum of 15. It has decreased from 21.01 (Mar 24) to 17.01, marking a decrease of 4.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.03. This value exceeds the healthy maximum of 3. It has decreased from 8.75 (Mar 24) to 8.03, marking a decrease of 0.72.
- For Retention Ratios (%), as of Mar 25, the value is 79.13. This value exceeds the healthy maximum of 70. It has increased from 66.80 (Mar 24) to 79.13, marking an increase of 12.33.
- For Price / BV (X), as of Mar 25, the value is 4.34. This value exceeds the healthy maximum of 3. It has decreased from 5.34 (Mar 24) to 4.34, marking a decrease of 1.00.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.03. This value exceeds the healthy maximum of 3. It has decreased from 8.75 (Mar 24) to 8.03, marking a decrease of 0.72.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Pfizer Ltd:
- Net Profit Margin: 33.64%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 19.61% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.2% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 71.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.33
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 31.9 (Industry average Stock P/E: 53.61)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 33.64%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | The Capital, 1802 / 1901, 18th Floor, Mumbai Maharashtra 400051 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradip Shah | Chairman & Ind.Director |
| Ms. Meenakshi Nevatia | Managing Director |
| Mr. P Rengan | Executive Director - Operations |
| Mr. Amit Agarwal | Executive Director & CFO |
| Ms. Meena Ganesh | Independent Director |
| Mr. Lakshmanan Krishnakumar | Independent Director |
| Ms. Sonia Singh | Independent Director |
FAQ
What is the intrinsic value of Pfizer Ltd?
Pfizer Ltd's intrinsic value (as of 08 January 2026) is ₹3544.81 which is 28.07% lower the current market price of ₹4,928.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹22,546 Cr. market cap, FY2025-2026 high/low of ₹5,993/3,701, reserves of ₹3,803 Cr, and liabilities of ₹4,606 Cr.
What is the Market Cap of Pfizer Ltd?
The Market Cap of Pfizer Ltd is 22,546 Cr..
What is the current Stock Price of Pfizer Ltd as on 08 January 2026?
The current stock price of Pfizer Ltd as on 08 January 2026 is ₹4,928.
What is the High / Low of Pfizer Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Pfizer Ltd stocks is ₹5,993/3,701.
What is the Stock P/E of Pfizer Ltd?
The Stock P/E of Pfizer Ltd is 31.9.
What is the Book Value of Pfizer Ltd?
The Book Value of Pfizer Ltd is 841.
What is the Dividend Yield of Pfizer Ltd?
The Dividend Yield of Pfizer Ltd is 0.71 %.
What is the ROCE of Pfizer Ltd?
The ROCE of Pfizer Ltd is 21.6 %.
What is the ROE of Pfizer Ltd?
The ROE of Pfizer Ltd is 16.4 %.
What is the Face Value of Pfizer Ltd?
The Face Value of Pfizer Ltd is 10.0.